{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:52:25Z","timestamp":1782226345924,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10637-021-01074-w","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T08:30:19Z","timestamp":1613291419000},"page":"1113-1122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial"],"prefix":"10.1007","volume":"39","author":[{"given":"Anas","family":"Alshawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Perez","family":"Cadena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito R.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey","family":"McQuinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie","family":"Lawhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrazzak","family":"Zarifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Maximilian","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senait","family":"Fessaheye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla L.","family":"Warneke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8435-2083","authenticated-orcid":false,"given":"Joe Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,13]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"1074_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/07357900701208758","volume":"25","author":"AR Jazieh","year":"2007","unstructured":"Jazieh AR, Younas A, Safa M, Redmond K, Buncher R, Howington J (2007) Phase I clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer. Cancer Investig 25:294\u2013298","journal-title":"Cancer Investig"},{"key":"1074_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cllc.2011.03.026","volume":"12","author":"M Werner-Wasik","year":"2011","unstructured":"Werner-Wasik M, Paulus R, Curran WJ Jr, Byhardt R (2011) Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer 12:245\u2013251","journal-title":"Clin Lung Cancer"},{"key":"1074_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.gtc.2005.12.011","volume":"35","author":"DD Howell","year":"2006","unstructured":"Howell DD (2006) The role of radiation therapy in the palliation of gastrointestinal malignancies. Gastroenterol Clin N Am 35:125\u2013130","journal-title":"Gastroenterol Clin N Am"},{"key":"1074_CR5","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/JCO.2007.15.3312","volume":"26","author":"A Fairchild","year":"2008","unstructured":"Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E (2008) Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 26:4001\u20134011","journal-title":"J Clin Oncol"},{"key":"1074_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.21037\/tlcr.2017.04.04","volume":"6","author":"TP Diwanji","year":"2017","unstructured":"Diwanji TP, Mohindra P, Vyfhuis M, Snider III JW, Kalavagunta C, Mossahebi S, Yu J, Feigenberg S, Badiyan SN (2017) Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Transl Lung Cancer Res 6:131\u2013147","journal-title":"Transl Lung Cancer Res"},{"key":"1074_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/ijms18051051","volume":"18","author":"MH Kim","year":"2017","unstructured":"Kim MH, Kim H (2017) The roles of glutamine in the intestine and its implication in intestinal diseases. Int J Mol Sci 18:1051","journal-title":"Int J Mol Sci"},{"key":"1074_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ijrobp.2007.03.041","volume":"69","author":"M Algara","year":"2007","unstructured":"Algara M, Rodriguez N, Vinals P et al (2007) Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys 69:342\u2013349","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1074_CR9","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3390\/nu12061675","volume":"12","author":"PM Anderson","year":"2020","unstructured":"Anderson PM, Lalla RV (2020) Glutamine for amelioration of radiation and chemotherapy associated Mucositis during Cancer therapy. Nutrients 12:1675","journal-title":"Nutrients"},{"key":"1074_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0305-7372(03)00133-6","volume":"29","author":"DM Savarese","year":"2003","unstructured":"Savarese DM, Savy G, Vahdat L et al (2003) Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29:501\u2013513","journal-title":"Cancer Treat Rev"},{"key":"1074_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/01635580701439632","volume":"59","author":"Y Kaufmann","year":"2007","unstructured":"Kaufmann Y, Klimberg VS (2007) Effect of glutamine on gut glutathione fractional release in the implanted tumor model. Nutr Cancer 59:199\u2013206","journal-title":"Nutr Cancer"},{"key":"1074_CR12","unstructured":"U.S. Department of Health and Human Services (2010) National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03"},{"key":"1074_CR13","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer patients: the M.D. Anderson symptom inventory. Cancer 89:1634\u20131646","journal-title":"Cancer"},{"key":"1074_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hed.20602","volume":"29","author":"DI Rosenthal","year":"2007","unstructured":"Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, Weber RS, Lewin JS, Garden AS, Ang KK, S. Wang X, Cleeland CS (2007) Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 29:923\u2013931","journal-title":"Head Neck"},{"key":"1074_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.lungcan.2008.06.015","volume":"63","author":"E Topkan","year":"2009","unstructured":"Topkan E, Yavuz MN, Onal C, Yavuz AA (2009) Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters. Lung Cancer 63:393\u2013399","journal-title":"Lung Cancer"},{"key":"1074_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2307\/2532056","volume":"45","author":"S Choi","year":"1989","unstructured":"Choi S, Pepple P (1989) Monitoring clinical trials based on predictive probability of significance. Biometrics 45:317\u2013323","journal-title":"Biometrics"},{"key":"1074_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/JIPO.JIPO_20_18","volume":"1","author":"A Naing","year":"2018","unstructured":"Naing A (2018) Being realistic and optimistic in curing cancer. J Immunother Precis Oncol 1:53\u201355","journal-title":"J Immunother Precis Oncol"},{"key":"1074_CR18","first-page":"119","volume":"7","author":"S Baker","year":"2016","unstructured":"Baker S, Fairchild A (2016) Radiation-induced esophagitis in lung cancer. Lung Cancer (Auckl) 7:119\u2013127","journal-title":"Lung Cancer (Auckl)"},{"key":"1074_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014463","volume":"98","author":"SC Chang","year":"2019","unstructured":"Chang SC, Lai YC, Hung JC, Chang CY (2019) Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer. Medicine (Baltimore) 98:e14463","journal-title":"Medicine (Baltimore)"},{"key":"1074_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.clnu.2016.06.012","volume":"36","author":"K Gul","year":"2017","unstructured":"Gul K, Mehmet K, Meryem A (2017) The effects of oral glutamine on clinical and survival outcomes of non-small cell lung cancer patients treated with chemoradiotherapy. Clin Nutr 36:1022\u20131028","journal-title":"Clin Nutr"},{"key":"1074_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/1471-2407-12-502","volume":"12","author":"E Topkan","year":"2012","unstructured":"Topkan E, Parlak C, Topuk S, Pehlivan B (2012) Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. BMC Cancer 12:502","journal-title":"BMC Cancer"},{"key":"1074_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/01635581.2013.765017","volume":"65","author":"A Vidal-Casariego","year":"2013","unstructured":"Vidal-Casariego A, Calleja-Fernandez A, Ballesteros-Pomar MD et al (2013) Efficacy of glutamine in the prevention of Oral Mucositis and acute radiation-induced esophagitis: a retrospective study. Nutr Cancer Int J 65:424\u2013429","journal-title":"Nutr Cancer Int J"},{"key":"1074_CR23","first-page":"6308","volume":"28","author":"M Wei","year":"2017","unstructured":"Wei M, Xie CH (2017) Weight loss predicts poor prognosis in patients treated with concurrent chemoradiotherapy for stage III non-small cell lung cancer. Biomed Res India 28:6308\u20136313","journal-title":"Biomed Res India"},{"key":"1074_CR24","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/S0360-3016(00)00801-4","volume":"48","author":"M Werner-Wasik","year":"2000","unstructured":"Werner-Wasik M, Scott C, Cox JD, Sause WT, Byhardt RW, Asbell S, Russell A, Komaki R, Lee JS (2000) Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48:1475\u20131482","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1074_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0360-3016(01)01713-8","volume":"51","author":"D Antonadou","year":"2001","unstructured":"Antonadou D, Coliarakis N, Synodinou M, Athanassiou H, Kouveli A, Verigos C, Georgakopoulos G, Panoussaki K, Karageorgis P, Throuvalas N (2001) Randomized phase III trial of radiation treatment +\/\u2212 amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51:915\u2013922","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1074_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S0360-3016(03)00590-X","volume":"57","author":"D Antonadou","year":"2003","unstructured":"Antonadou D, Throuvalas N, Petridis A, Bolanos N, Sagriotis A, Synodinou M (2003) Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57:402\u2013408","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1074_CR27","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.ijrobp.2003.10.005","volume":"58","author":"R Komaki","year":"2004","unstructured":"Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58:1369\u20131377","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1074_CR28","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1200\/JCO.2005.07.167","volume":"23","author":"B Movsas","year":"2005","unstructured":"Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145\u20132154","journal-title":"J Clin Oncol"},{"key":"1074_CR29","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2003.11.005","volume":"21","author":"SS Leong","year":"2003","unstructured":"Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, Chew L, Lim SH, Wee J, Lee KM, Foo KF, Ang P, Ang PT (2003) Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21:1767\u20131774","journal-title":"J Clin Oncol"},{"key":"1074_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/sonc.2002.37362","volume":"29","author":"N Senzer","year":"2002","unstructured":"Senzer N (2002) A phase III randomized evaluation of amifostine in stage IIIA\/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. Semin Oncol 29:38\u201341","journal-title":"Semin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01074-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01074-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01074-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:06:33Z","timestamp":1678511193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01074-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,13]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01074-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,13]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Institutional Review Board at MD Anderson and was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. All study participants provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study participants provided written informed consent before enrollment which include consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Aung Naing: research funding from NCI; EMD Serono; MedImmune; Healios Onc. Nutrition; Atterocor\/Millendo; Amplimmune; ARMO BioSciences; Karyopharm Therapeutics; Incyte; Novartis; Regeneron; Merck; BMS; Pfizer, CytomX Therapeutics; Neon Therapeutics; Calithera Biosciences; TopAlliance Biosciences; Eli Lilly; Kymab; PsiOxus; Arcus Biosciences; NeoImmuneTech; ImmuneOncia; Surface Oncology. On advisory board of CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695 and Kymab. Travel and accommodation expense from ARMO BioSciences.Dr. Aung Naing\u2019s Spouse: Dr. Joud Hajjar: research funding: Immune Deficiency Foundation, Jeffery Modell Foundation and chao physician-scientist, and Baxalta. Advisory board: Takeda, CSL, Behring, Horizon, and Pharming.No other conflict of interest or competing interests to disclose for all other authors and statements has been provided.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}